Severe Respiratory Diseases
Zambon is continually searching for solutions, which will make patients’ lives better for those affected by severe respiratory diseases such as CF, BOS and NCFB.
Around 100,000 people worldwide suffer from Cystic Fibrosis, the most common severe genetic disease. This multi-organ disease mainly affects the lungs, which are hit by chronic infections and inflammations that cause their progressive deterioration.
*Sources: ECFS Patient Registry, Report 2015
New cases of Cystic Fibrosis every year in Italy
Cases of Cystic Fibrosis affecting children in Europe
We want to develop treatments that play a key role in treating Cystic Fibrosis, as well as in managing severe respiratory diseases
Bronchiolitis Obliterans Syndrome (BOS)
BOS is a rapidly progressive disease that usually leads to respiratory failure and death within one to two years after diagnosis. BOS is caused by an inflammatory process triggered by the immune system that irreversibly destroys the airways of the lungs. BOS is most commonly seen in patients following lung transplantation and allogeneic hematopoietic stem cell transplant, though it is also associated with autoimmune disease and exposure to environmental contaminants.
develop BOS by 10 years post lung transplantation
rate of 5 years BOS patients' survival
Zambon is supporting a full clinical development plan worldwide
Lung transplant survival is limited and has failed to improve substantially during the past two decades. Bronchiolitis obliterans is a leading cause of death. Inhalation of cyclosporine provides high bronchiolar concentrations and may arrest BOS progression. Zambon is supporting a full clinical development plan worldwide to unveil the clinical benefit of using liposomal cyclosporine inhaled formulation in patients after lung and after hematopoietic stem cell transplantation.